[
    [
        {
            "time": "",
            "original_text": "医药生物行业2021年下半年投资策略：短期有扰动 长期发展趋势向好",
            "features": {
                "keywords": [
                    "医药生物",
                    "2021年下半年",
                    "投资策略",
                    "短期扰动",
                    "长期趋势"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业2021年下半年投资策略：短期有扰动 长期发展趋势向好",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 5,
                "Duration": 9,
                "Entity_Density": 3,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(002821)：股权激励常态化 为中长期快速发展夯实基础",
            "features": {
                "keywords": [
                    "凯莱英",
                    "股权激励",
                    "中长期发展",
                    "快速成长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "凯莱英(002821)：股权激励常态化 为中长期快速发展夯实基础",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "浙商证券：凯莱英（002821.SZ）激励常态化，看好2021年业绩加速，维持“买入”评级",
            "features": {
                "keywords": [
                    "浙商证券",
                    "凯莱英",
                    "股权激励",
                    "2021年业绩",
                    "买入评级"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "浙商证券：凯莱英（002821.SZ）激励常态化，看好2021年业绩加速，维持“买入”评级",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]